Login to Your Account



Twitter peeps wing it on Verastem abstract; 'overdo' phase II NSCLC defactinib migration

By Randy Osborne
Staff Writer

Thursday, August 27, 2015

Verastem Inc. shares began climbing out of the hole dug Wednesday by Twitter wags who chastised the firm about the deaths in a phase II trial with defactinib of two late-stage lung cancer patients who "were really pretty sick in many different ways" beyond their primary disease, CEO Robert Forrester told BioWorld Today.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription